ENGLEWOOD, Colo., June 16, 2015 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today provided shareholders information on the formation and recent activities of Aytu BioScience, Inc. (OTCMKTS: RSWND); (http://aytubio.com/ ), a specialty healthcare company focused on developing treatments for urological and related conditions. Aytu was founded on therapeutic and diagnostic assets previously owned by Ampio Pharmaceuticals. Ampio CEO Michael Macaluso explained, "Ampio owns 81.5 percent of Aytu Bioscience, an emerging specialty healthcare company with an experienced executive management team. We believe Aytu will provide Ampio shareholders a better return, allowing Ampio to concentrate on the development of near-term assets, Ampion ™ and Optina ™ – two investigational compounds being tested for the treatment of prevalent inflammatory conditions for which there are limited treatment options."